PMID- 21908416
OWN - NLM
STAT- MEDLINE
DCOM- 20120914
LR  - 20220311
IS  - 1460-2385 (Electronic)
IS  - 0931-0509 (Linking)
VI  - 27
IP  - 3
DP  - 2012 Mar
TI  - Long-term mineralocorticoid receptor blockade ameliorates progression of 
      experimental diabetic renal disease.
PG  - 906-12
LID - 10.1093/ndt/gfr495 [doi]
AB  - The final end point of diabetic renal disease is the accumulation of excess 
      collagen. A number of studies have shown that aldosterone antagonism ameliorates 
      progression of renal fibrosis. This study was designed to examine the effect of 
      the mineralocorticoid receptor blocker eplerenone (EPL) on progression in 
      streptozotocin (STZ)-treated spontaneously hypertensive rats (SHR), an 
      accelerated model of Type I diabetes. STZ-treated SHRs with a blood glucose >18 
      mmol/L were randomly divided into treatment (100 mg/kg/day EPL) and non-treatment 
      groups. Sham-injected SHR animals were used as a control. Functional parameters 
      were monitored for 16 weeks, with structural parameters assessed at completion. 
      Both hyperglycaemic groups developed progressive albuminuria, but the increase 
      was ameliorated by EPL from Week 12. STZ-SHRs had elevated kidney weight/body 
      weight ratio, glomerular size, glomerular macrophages (ED-1-positive cells), 
      tissue transforming growth factor beta 1 (TGFbeta1) concentrations and glomerular 
      collagen IV staining (all P < 0.05 versus control animals). EPL reduced 
      glomerular volume, TGFbeta1 expression and glomerular collagen IV without changing 
      glomerular macrophage infiltration. The ability of EPL to ameliorate these 
      functional and structural changes in hyperglycaemic SHRs suggest that EPL has a 
      renoprotective role in diabetic renal disease.
FAU - Lian, Michael
AU  - Lian M
AD  - Department of Nephrology, The Royal Melbourne Hospital, University of Melbourne, 
      Melbourne, Australia.
FAU - Hewitson, Tim D
AU  - Hewitson TD
FAU - Wigg, Belinda
AU  - Wigg B
FAU - Samuel, Chrishan S
AU  - Samuel CS
FAU - Chow, Fiona
AU  - Chow F
FAU - Becker, Gavin J
AU  - Becker GJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110908
PL  - England
TA  - Nephrol Dial Transplant
JT  - Nephrology, dialysis, transplantation : official publication of the European 
      Dialysis and Transplant Association - European Renal Association
JID - 8706402
RN  - 0 (Collagen Type IV)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 27O7W4T232 (Spironolactone)
RN  - 4964P6T9RB (Aldosterone)
SB  - IM
MH  - Aldosterone/blood
MH  - Animals
MH  - Blood Pressure
MH  - Blotting, Western
MH  - Collagen Type IV/metabolism
MH  - Diabetes Mellitus, Experimental/*physiopathology
MH  - Diabetic Nephropathies/*pathology/*prevention & control
MH  - Disease Progression
MH  - Female
MH  - Hyperglycemia/metabolism/pathology
MH  - *Mineralocorticoid Receptor Antagonists
MH  - Rats
MH  - Rats, Inbred SHR
MH  - Spironolactone/*therapeutic use
MH  - Time Factors
MH  - Transforming Growth Factor beta1/metabolism
EDAT- 2011/09/13 06:00
MHDA- 2012/09/15 06:00
CRDT- 2011/09/13 06:00
PHST- 2011/09/13 06:00 [entrez]
PHST- 2011/09/13 06:00 [pubmed]
PHST- 2012/09/15 06:00 [medline]
AID - gfr495 [pii]
AID - 10.1093/ndt/gfr495 [doi]
PST - ppublish
SO  - Nephrol Dial Transplant. 2012 Mar;27(3):906-12. doi: 10.1093/ndt/gfr495. Epub 
      2011 Sep 8.